Amalgamated Financial’s Nurix Therapeutics NRIX Stock Holding History

Amalgamated Financial’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$70K	Buy	+4,981	New	+$88.4K	﹤0.01%	2269

Other funds holding NRIX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Amalgamated Financial's NRIX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Nurix Therapeutics (NRIX) in Q1 2022: 4,981 shares worth $70K. The stake represents ﹤0.01% of the portfolio and ranks #2269 among its holdings.

117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

Amalgamated Financial held 4,981 shares of Nurix Therapeutics worth $70K as of Q1 2022.
Nurix Therapeutics was a new Amalgamated Financial position in Q1 2022.
Nurix Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2269 holding.
117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.